Please login to the form below
Pascal Soriot
This page shows the latest Pascal Soriot news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca announces launch of new healthtech business Evinova to optimise clinical trials
Pascal Soriot, chief executive officer, AZ, said: “We believe Evinova’s combination of scientific expertise and track record in developing AI-enabled digital technologies at scale provides a real opportunity to
Latest news
-
AstraZeneca unveils plans for new US R&D centre
Pascal Soriot, CEO, AstraZeneca, said: “Our combined company has already successfully leveraged internal scientific synergies, and this move will act as a catalyst for even more external collaboration and innovation.
-
AstraZeneca officially opens new R&D facility in UK
CEO Pascal Soriot said AZ’s ambition was to “drive the next wave” of scientific innovation.
-
AstraZeneca signs for-profit agreements for its COVID-19 vaccine
Our broad portfolio of medicines and diversified geographic exposure provides a robust platform for long-term sustainable growth,” said CEO, Pascal Soriot. ... Soriot stressed that this was always the company’s plan for the vaccine.
-
AZ raises full-year guidance after completing Alexion acquisition in Q2
As a result, we have delivered further earnings progression, supported ongoing launches, and continued our investment in R&D,” said Pascal Soriot, chief executive officer of AZ.
-
AstraZeneca reports ‘strong’ Q1 results, forecasts accelerated growth in 2021
We expect the impact of COVID-19 to reduce and anticipate a performance acceleration in the second half of 2021,” said Pascal Soriot, chief executive officer of AZ.
More from news
Approximately 1 fully matching, plus 107 partially matching documents found.
Latest Intelligence
-
20 for 2020 – Five pharma companies to watch
to outperform all its big pharma peers in 2020. It’s been an incredible turnaround for the company under CEO Pascal Soriot from a few short years ago, when its future
-
Leading AstraZeneca’s return to growth in Europe
Our CEO Pascal Soriot chairs quarterly meetings of our Global Inclusion and Diversity council, the group that sets our Global standards and steers implementation on inclusion and diversity.
-
The Orkambi blame game
CEO Ian Read and AstraZeneca’s Pascal Soriot about the former’s hostile takeover bid in 2014 being the only similar example from recent history.
-
AstraZeneca: building a new ‘open innovation’ pharma company
Regardless, the company hasn’t been waiting for the HQ to be completed to rebuild its business; CEO since 2012, Pascal Soriot is leading the company in renewing its place among ... revenues in its oncology division grew by 42% in the first half of this
-
China: AstraZeneca’s new engine for growth and innovation
AstraZeneca China’s HQ in Shanghai Zhangjiang Hi-Tech Park. Back in 2014, when AstraZeneca’s chief executive Pascal Soriot was fending off a hostile takeover bid from Pfizer, he pledged
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
AZ appoints Susan Galbraith as executive vice president, oncology R&D
Over the past decade at AstraZeneca, she has developed new medicines that have transformed care and improved the lives of patients around the world,” said Pascal Soriot, chief executive officer of
-
AZ appoints Alexion’s Aradhana Sarin as chief financial officer
Meanwhile, Sarin will relocate from the US to be based in the UK, and will report to AZ’s chief executive officer Pascal Soriot. ... I’d like to pay tribute to Marc for his tremendous achievements since he joined our company, and thank him personally
-
AstraZeneca appoints Sean Bohen as chief medical officer
Pascal Soriot, CEO at AZ, said: “I'm delighted to welcome Sean to AstraZeneca at a very exciting time for our company.
-
AZ appoints Pam Cheng as executive VP, operations and IT
Pascal Soriot, CEO at AZ, commented: “I am delighted to welcome Pam to AstraZeneca at a very exciting time for our business.
-
Senior AstraZeneca exec jumps ship to small biotech
AstraZeneca's chief executive, Pascal Soriot, will take over the job of late-stage drug development on an interim basis, according to news reports. ... Colin White, an analyst at Datamonitor Healthcare, said: “It is surprising because he was brought
More from appointments
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest from PMHub
-
A masterclass in corporate communications
If you only read one thing this week, make it AstraZeneca CEO Pascal Soriot’s interview in La Repubblica. ... Soriot likely had a very clear idea of which questions would be asked so that he could prepare thoroughly for them.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
The Good Ideas Group
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
